Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization

BioTechniques

Volumn 52, Issue 4, 2012, Pages 235-245

  Hanna, Jason A ^a   Wimberly, Hallie ^a   Kumar, Salil ^a   Slack, Frank ^b   Agarwal, Seema ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

ISH; miR 221; miRNA; Tissue microarrays

Indexed keywords

CYTOKERATIN; ESTROGEN RECEPTOR ALPHA; MICRORNA; MICRORNA 21; MICRORNA 221; MICRORNA 34A; MICRORNA 92A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; EPITHELIUM; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; VALIDITY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MICE; MICE, KNOCKOUT; MICRORNAS; NEOPLASM PROTEINS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 84859454379     PISSN: 07366205     EISSN: 19409818     Source Type: Journal    
DOI: 10.2144/000113837     Document Type: Article

References (45)

1. Croce, C.M. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10:704-714.
2. Lewis, B.P., C.B. Burge, and D.P. Bartel. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20.
3. Friedman, R.C., K.K. Farh, C.B. Burge, and D.P. Bartel. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92-105.
4. Esquela-Kerscher, A. and F.J. Slack. 2006. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6:259-269.
5. Gupta, A. and Y.Y. Mo. 2011. Detection of microRNAs in cultured cells and paraffin-embedded tissue specimens by in situ hybridization. Methods Mol. Biol. 676:73-83.
6. Jorgensen, S., A. Baker, S. Moller, and B.S. Nielsen. 2010. Robust one-day in situ hybrid-ization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52:375-381.
7. Nuovo, G.J. 2010. In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods 52:307-315.
8. Sempere, L.F., M. Christensen, A. Silahtaroglu, M. Bak, C.V. Heath, G. Schwartz, W. Wells, S. Kauppinen, and C.N. Cole. 2007. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 67:11612-11620.
9. Sempere, L.F., M. Preis, T. Yezefski, H. Ouyang, A.A. Suriawinata, A. Silahtaroglu, J.R. Conejo-Garcia, S. Kauppinen, et al. 2010. Fluorescence based codetection with protein markers reveals distinct cellular compartments for alteredMicroRNA expression in solid tumors. Clin. Cancer Res. 16:4246-4255.
10. Singh, S.K., R. Kumar, and J. Wengel. 1998. Synthesis of Novel Bicyclo[2.2.1] Ribonucleo- sides: 2'-Amino- and 2'-Thio-LNA Monomeric Nucleosides. J. Org. Chem. 63:6078-6079.
11. Pena, J.T., C. Sohn-Lee, S.H. Rouhanifard, J. Ludwig, M. Hafner, A. Mihailovic, C. Lim, D. Holoch, et al. 2009. miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat. Methods 6:139-141.
12. Rimm, D.L. 2006. What brown cannot do for you. Nat. Biotechnol. 24: 914-916.
13. Rothberg, B.E., C.B. Moeder, H. Kluger, R. Halaban, D.E. Elder, G.F. Murphy, A. Lazar, V. Prieto, et al. 2008. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod. Pathol. 21:1121-1129.
14. Welsh, A.W., C.B. Moeder, S. Kumar, P. Gersh-kovich, E.T. Alarid, M. Harigopal, B.G. Haffty, and D.L. Rimm. 2011. Standardization ofestrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J. Clin. Oncol. 29:2978-2984.
15. Camp, R.L., G.G. Chung, and D.L. Rimm. 2002. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8:1323-1327.
16. Neumeister, V., S. Agarwal, J. Bordeaux, R.L. Camp, and D.L. Rimm. 2010. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol. 176:2131-2138.
17. Anagnostou, V.K., A.T. Dimou, T. Botsis, E.J. Killiam, M.D. Gustavson, R.J. Homer, D. Boffa, V. Zolota, et al. 2011. Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay. Cancer. 118(6):1607-18
18. Knudsen, B.S., P. Zhao, J. Resau, S. Cottingham, E. Gherardi, E. Xu, B. Berghuis, J. Daugherty, et al. 2009. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl. Immunohistochem. Mol. Morphol. 17:57-67.
19. Al-Nakhle, H., P.A. Burns, M. Cummings, A.M. Hanby, T.A. Hughes, S. Satheesha, A.M. Shaaban, L. Smith, and V. Speirs. 2010. Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res. 70:4778-4784.
20. Iorio, M.V., M. Ferracin, C.G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, et al. 2005. MicroRNA gene expression dereg-ulation in human breast cancer. Cancer Res. 65:7065-7070.
21. Lodygin, D., V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Korner, P. Knyazev, J. Diebold, and H. Hermeking. 2008. Inacti-vation of miR-34a by aberrant CpG methy-lation in multiple types of cancer. Cell Cycle 7:2591-2600.
22. Zhao, J.J., J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, and J.Q. Cheng. 2008. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079-31086.
23. Hwang, H.W., E.A. Wentzel, and J.T. Mendell. 2007. A hexanucleotide element directs microRNA nuclear import. Science 315:97-100.
24. Jeffries, C.D., H.M. Fried, and D.O. Perkins. 2011. Nuclear and cytoplasmic localization of neural stem cell microRNAs. RNA 17:675-686.
25. Robb, G.B., K.M. Brown, J. Khurana, and T.M. Rana. 2005. Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol. 12:133-137.
26. Patrick, D.M., R.L. Montgomery, X. Qi, S. Obad, S. Kauppinen, J.A. Hill, E. van Rooij, and E.N. Olson. 2010. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120:3912-3916.
27. Corney, D.C., C.I. Hwang, A. Matoso, M. Vogt, A. Flesken-Nikitin, A.K. Godwin, A.A. Kamat, A.K. Sood, et al. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16:1119-1128.
28. Meng, F., R. Henson, H. Wehbe-Janek, K. Ghoshal, S.T. Jacob, and T. Patel. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658.
29. Migliore, C., A. Petrelli, E. Ghiso, S. Corso, L. Capparuccia, A. Eramo, P.M. Comoglio, and S. Giordano. 2008. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 68:10128-10136.
30. Barh, D., S. Parida, B.P. Parida, and G. Viswa-nathan. 2008. Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine. Gene Ther. Mol. Biol. 12B:189-206.
31. Greene, S.B., J.I. Herschkowitz, and J.M. Rosen. 2010. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 7:300-304.
32. Gregory, P.A., A.G. Bert, E.L. Paterson, S.C. Barry, A. Tsykin, G. Farshid, M.A. Vadas, Y. Khew-Goodall, and G.J. Goodall. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10:593-601.
33. Wu, H., S. Zhu, and Y.Y. Mo. 2009. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19:439-448.
34. Mukherji, S., M.S. Ebert, G.X. Zheng, J.S. Tsang, P.A. Sharp, and A. van Oudenaarden. 2011. MicroRNAs can generate thresholds in target gene expression. Nat. Genet. 43:854-859.
35. Karreth, F.A., Y. Tay, D. Perna, U. Ala, S.M. Tan, A.G. Rust, G. Denicola, K.A. Webster, et al. 2011. In Vivo Identification of Tumor-Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell 147:382-395.
36. Miller, T.E., K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C.L. Shapiro, S. Jacob, and S. Majumder. 2008. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283:29897-29903.
37. Rao, X., G. Di Leva, M. Li, F. Fang, C. Devlin, C. Hartman-Frey, M.E. Burow, M. Ivan, et al. 2011. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30:1082-1097.
38. Yoshimoto, N., T. Toyama, S. Takahashi, H. Sugiura, Y. Endo, M. Iwasa, Y. Fujii, and H. Yamashita. 2011. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Treat. 130(1):331-9
39. Duncavage, E., B. Goodgame, A. Sezhiyan, R. Govindan, and J. Pfeifer. 2010. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J. Thorac. Oncol. 5:1755-1763.
40. Spahn, M., S. Kneitz, C.J. Scholz, N. Stenger, T. Rudiger, P. Strobel, H. Riedmiller, and B. Kneitz. 2010. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127:394-403.
41. Yan, L.X., X.F. Huang, Q. Shao, M.Y. Huang, L. Deng, Q.L. Wu, Y.X. Zeng, and J.Y. Shao. 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metas-tasis and patient poor prognosis. RNA 14:2348-2360.
42. Chen, C., D.A. Ridzon, A.J. Broomer, Z. Zhou, D.H. Lee, J.T. Nguyen, M. Barbisin, N.L. Xu, et al. 2005. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e179.
43. Jang, J.S., V.A. Simon, R.M. Feddersen, F. Rakhshan, D.A. Schultz, M.A. Zschunke, W.L. Lingle, C.P. Kolbert, and J. Jen. 2011. Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics 12:144.
44. Shippy, R., T.J. Sendera, R. Lockner, C. Palaniappan, T. Kaysser-Kranich, G. Watts, and J. Alsobrook. 2004. Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics 5:61.
45. Tang, F., P. Hajkova, S.C. Barton, D. O'Carroll, C. Lee, K. Lao, and M.A. Surani. 2006. 220-plex microRNA expression profile of a single cell. Nat. Protocols 1:1154-1159.